| P5 Evidence for Decision Making | David Kaslow, Robert Breiman | | Report | Anglais |
| P6 Polio Endgame: Needs and Opportunities | Roland Sutter | | Report | Anglais |
| W9.4 Antibody Engineering: Optimization of Antibodies for Commercialization | Stephen Hadley | 2018 | Presentation | Anglais |
| W9.3 Monoclonal Antibodies for Influenza Prevention, Therapy, or Vaccine Antigen Design | Bruce Innis | 2018 | Presentation | Anglais |
| W9.2 Monoclonal antibodies for rabies post-exposure prophylaxis | Erin Sparrow | 2018 | Presentation | Anglais |
| W9.1 Pipeline of HIV monoclonal antibodies for prevention of HIV | Barney Graham | 2018 | Presentation | Anglais |
| W8.3 The Principle and Process of Autogenous Vaccine | Suphot Wattanaphansak | 2018 | Presentation | Anglais |
| W8.2 Vaccination against bacterial diseases in farmed Atlantic salmon: experience and global applicability | Edgar Brun | 2018 | Presentation | Anglais |
| W8.1 Antimicrobial Resistance and Vaccines | Dennis Dixon | 2018 | Presentation | Anglais |
| W7.5 Target Value Proposition | Jean Lang | 2018 | Presentation | Anglais |
| W7.4 Human Hookworm Vaccine Initiative: a Public Health value proposition leading to societal impact and positive financial returns | Maria Elena Bottazzi | 2018 | Presentation | Anglais |
| W7.3 A Hepatitis C Virus Vaccine Update | Andrea Cox | 2018 | Presentation | Anglais |
| W7.2 Update on RSV Vaccine and mAb development | Ruth Karron | 2018 | Presentation | Anglais |
| W7.1 Global Vaccine Pipeline and Value Proposition | David Kaslow | 2018 | Presentation | Anglais |
| W6.3 Maternal and adolescents immunization - a global challenge | Raymond Hutubessy | 2018 | Presentation | Anglais |
| W6.2 Adolescent Immunization in Developing Countries: Obstacles and Opportunities | Hartono Gunardi | 2018 | Presentation | Anglais |
| W6.1 Reaching Adolescents & Pregnant Women (Introduction) | Odile Leroy | 2018 | Presentation | Anglais |
| W5.4 Universal Influenza Vaccines and Their Role in Preparedness | Jennifer Gordon | 2018 | Presentation | Anglais |
| W5.3 Epidemic Preparedness: National Security for Thailand | Punee Pitisuttithum | 2020 | Presentation | Anglais |
| W5.2 Influenza Pandemic Risk and Preparedness | John S. Tam | 2018 | Presentation | Anglais |
| W5.1 WHO R&D Blueprint Update: progress and Plans | Martin Friede | 2018 | Presentation | Anglais |
| W4.4 RTS,S Malaria Vaccine: Toward an understanding of the immunologic basis of protection | Christian Ockenhouse | 2018 | Presentation | Anglais |
| W4.3 New technologies for studying human immunity | Lisa Wagar | 2018 | Presentation | Anglais |
| W4.1 New Approaches to Understanding Human Immunity | Annie Mo | 2018 | Presentation | Anglais |
| W3.3 The Future of Pneumococcal Conjugate Vaccines | Keith Klugman | 2018 | Presentation | Anglais |
| W3.2 Rollout of Pneumococcal Conjugate Vaccine in India | Narendra K Arora, Pradeep Haldar | 2018 | Presentation | Anglais |
| W3.1 2018 Status of Pneumococcal Conjugate Vaccine Use and Impact | Katherine L. O'Brien | 2018 | Presentation | Anglais |
| W2.3 Controlled Human Infection Models and Enteric Vaccine Development | Beth Kirkpatrick | 2018 | Presentation | Anglais |
| W2.2 Subunit vaccine technologies for bacterial enteric diseases: Shigella, ETEC and nontyphoidal Salmonella vaccines | Cal MacLennan | 2018 | Presentation | Anglais |
| W2.1 An update on rotavirus vaccines | Gagandeep Kang | 2018 | Presentation | Anglais |
| W1.3 A novel vaccine technology platform Plasmid Launched Live Attenuated Virus (PLLAV) Vaccines | Johan Neyts, Kai Dallmeier | 2018 | Presentation | Anglais |
| W1.2 New Vaccine Strategies using cytomegalovirus | Klaus Früh | 2018 | Presentation | Anglais |
| W1.1 MIMIC: an in vitro model of human immunity | Don Drake | 2018 | Presentation | Anglais |
| W9 Antibody-Mediated Prevention | Nina Russell | 2018 | Report | Anglais |
| W8 Vaccines and Antimicrobial Resistance (AMR) | A. A. Adeyemo | 2018 | Report | Anglais |
| W7 New Vaccine Pipeline: Lessons Learned and Accelerating Progress | Jean-Pierre Amorij | 2018 | Report | Anglais |
| W6 Reaching Adolescents and Pregnant Women | Odile Leroy | 2018 | Report | Anglais |
| W5 Epidemic and Pandemic Preparedness | Martin Friede | 2018 | Report | Anglais |
| W4 Immunological Principles of Vaccines and Vaccination | Annie Mo, Bernhards Ogutu | 2018 | Report | Anglais |
| W3 Pneumococcal Vaccines: Lessons Learned and the Road Ahead | Hani Kim | 2018 | Report | Anglais |
| W1 Emerging Vaccine Strategies & Technologies | Paula Bryant | 2018 | Report | Anglais |
| P7 Discussion with Thought Leaders | Peter Dull | 2018 | Report | Anglais |
| P6.5 Research for polio policy making: Lessons learned | Roland Sutter | 2018 | Presentation | Anglais |
| P6.4 Polio Vaccines - R&D Updates | Peter Dull | 2018 | Presentation | Anglais |
| P6.3 Two years after the tOPV ot bOPV switch: What happened to Poliovirus Type 2? | Ondrej Mach | 2018 | Presentation | Anglais |
| P6.2 Global tOPV withdrawal: "The Switch" experience | Alejandro Ramirez Gonzalez | 2018 | Presentation | Anglais |
| P6.1 Intro Polio Endgame: Needs and Opportunities | Roland Sutter | 2018 | Presentation | Anglais |
| P5.2 Evidence for Decision Making | Yot Teerawattananon | 2018 | Presentation | Anglais |
| P5.1 Development of WHO Full Public Health Value Propositions for vaccines to prevent infectious diseases | David Kaslow | 2018 | Presentation | Anglais |
| P4.3 Human Clinical Trial to Support the Development of New Vaccines: Perspective from Thailand | Akanid Wapeewuttikorn | 2018 | Presentation | Anglais |
